PTPN1 and metabolic dysfunction-associated steatotic liver disease: PTP1B inhibitors have been incorporated into various preclinical trials, and their effectiveness has been established by exhibiting a reduction in body weight, improvement in insulin sensitivity, and eradication of NAFLD.